Checkpoint Therapeutics Company Overview
About Checkpoint Therapeutics
Checkpoint Therapeutics (NASDAQ:CKPT) is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company is dedicated to advancing a diverse portfolio of immuno-oncology and targeted cancer therapies aiming to address the unmet medical needs of patients. With a strategic approach to drug development, Checkpoint Therapeutics is actively working on bringing innovative cancer treatments through clinical trials with the ultimate goal of improving patient outcomes. Their projects span from early to late-stage clinical trials, focusing on key areas such as non-small cell lung cancer and cutaneous T-cell lymphoma. The objective of Checkpoint Therapeutics is to leverage its expertise to develop and commercialize life-enhancing cancer treatments globally.
Snapshot
Operations
Products and/or services of Checkpoint Therapeutics
- Cosibelimab, a monoclonal antibody targeting PD-L1 for treating metastatic cutaneous squamous cell carcinoma.
- Olafertinib, an EGFR mutation inhibitor aimed at non-small cell lung cancer with specific genetic alterations.
- CK-101, a third-generation EGFR inhibitor for lung cancer patients resistant to first-line treatments.
- CK-103, a BET inhibitor designed for the treatment of solid tumors and hematologic malignancies.
- CK-302, an anti-GITR monoclonal antibody in development for various advanced cancers.
- CK-303, a novel antibody-drug conjugate targeting cancer cells with minimal impact on healthy tissue.
Checkpoint Therapeutics executive team
- Mr. James F. Oliviero III, C.F.A.President, CEO & Director